Endocrine Testing Market Set to Grow at 8.2% CAGR Through 2032, Says Persistence Market Research

The global endocrine testing market is experiencing unprecedented growth as healthcare systems prioritize early diagnosis and management of hormonal disorders. Endocrine testing involves assessing hormone levels to evaluate glandular function, essential in diagnosing conditions such as diabetes, thyroid dysfunction, adrenal insufficiency, and polycystic syndrome (PCOS). According to Persistence Market Research, the market was valued at US$ 13.4 Bn in 2025 and is projected to reach US$ 23.2 Bn by 2032, expanding at a compound annual growth rate (CAGR) of 8.2%.

The market's growth is significantly driven by the rising prevalence of hormone-related disorders, increasing health awareness, and rapid technological advancements in diagnostic solutions. The thyroid-stimulating hormone (TSH) test leads the market in terms of volume and revenue share, accounting for nearly 29.4% of total tests due to the increasing global incidence of thyroid disorders. Regionally, North America dominates the global endocrine testing market, attributed to advanced healthcare infrastructure, higher awareness levels, and robust research and development activity in the region.

✅Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/35201

Key Highlights from the Report

✦ Growing prevalence of diabetes and thyroid dysfunction fuels the demand for endocrine testing.
✦ Technological innovations in mass spectrometry and AI diagnostics enhance testing accuracy.
✦ Surge in demand for portable and home-based testing kits improves patient accessibility.
✦ Rising cases of obesity and metabolic disorders necessitate hormonal health monitoring.
✦ Healthcare investment, insurance coverage, and diagnostics funding bolster market expansion.
✦ Asia Pacific and Latin America emerge as high-growth markets due to improved healthcare access.

Market Segmentation

The endocrine testing market is segmented based on test types, technology, disease indication, and end-use. Among test types, the thyroid-stimulating hormone (TSH) test holds the largest share due to its critical role in diagnosing and managing thyroid disorders like hypothyroidism and hyperthyroidism. Tests for insulin, cortisol, estrogen, and testosterone are also witnessing rising demand, reflecting the broader spectrum of hormone-related diseases now being diagnosed.

From a technology standpoint, tandem mass spectrometry (MS/MS) has become the gold standard due to its precision and capacity for multiplex analysis. This method significantly enhances the reliability of results, especially when testing for multiple hormones simultaneously. Immunoassays, though widely used, are gradually being supplemented or replaced by MS/MS for more accurate detection.

In terms of end-use, diagnostic laboratories hold the majority share, followed by hospitals and clinics. The rise of at-home testing kits and point-of-care testing platforms is transforming patient behavior, with consumers seeking convenient, real-time hormone monitoring solutions. These kits have seen significant uptake for monitoring fertility, thyroid function, and stress hormones.

Regional Insights

North America

North America continues to lead the global endocrine testing market due to the high incidence of hormonal disorders and strong demand for early diagnostics. The presence of key diagnostic players, coupled with widespread healthcare awareness and insurance coverage, makes the region a frontrunner. Recent data from the American Cancer Society forecasts 44,020 new thyroid cancer cases in the U.S. in 2025, underlining the urgent need for accurate endocrine screening.

Europe

In Europe, the market is expanding rapidly due to increasing obesity rates and their link to endocrine dysfunction. OECD projects that by 2030, more than half of Europe's population may be obese, with corresponding increases in related hormonal disorders. The region benefits from advanced healthcare systems, frequent screening programs, and strategic partnerships between public health agencies and diagnostic providers.

Asia Pacific

Asia Pacific is emerging as the fastest-growing region in the endocrine testing space. Countries like China and India are experiencing an upsurge in diabetes and thyroid dysfunction due to lifestyle changes and aging populations. Government health initiatives and healthcare reforms are accelerating market penetration. The introduction of affordable diagnostic solutions and rising public awareness are creating vast opportunities for both global and regional players.

Middle East and Africa (MEA)

MEA is witnessing increased demand for endocrine testing due to rising rates of obesity, lifestyle diseases, and the booming medical tourism industry. Countries such as the UAE and Saudi Arabia are heavily investing in healthcare infrastructure, including AI-driven diagnostics and point-of-care testing. Remote and underserved areas are now gaining access to hormone screening through portable diagnostic kits.

Latin America (LATAM)

The Latin American market is also growing, particularly in Brazil and Mexico, driven by high diabetes prevalence and increased focus on preventive healthcare. Government-backed initiatives to expand healthcare access and promote early diagnosis are supporting market growth. Furthermore, medical tourism in the region is enhancing the demand for specialized testing services, including endocrine diagnostics.

Market Drivers

The endocrine testing market is propelled by increasing awareness and the growing emphasis on early diagnosis of hormonal imbalances. Lifestyle shifts, rising stress levels, and aging populations are contributing to a surge in endocrine disorders globally. Proactive healthcare approaches, such as routine screenings and preventive diagnostics, are gaining popularity, boosting the demand for hormone testing kits. Technological innovations in multiplex assays and AI-powered testing platforms are making diagnostics more accurate and accessible. The increased availability of point-of-care testing and home kits further enhances patient convenience, driving widespread market adoption.

Market Restraints

Despite its positive growth trajectory, the endocrine testing market faces several restraints. High costs associated with advanced diagnostic technologies and the need for specialized equipment hinder adoption, particularly in developing regions. Limited awareness and inadequate screening infrastructure in rural and low-income areas further exacerbate the issue. Additionally, the complexity of certain endocrine tests, regulatory compliance requirements, and reimbursement limitations pose operational and financial challenges for smaller laboratories and clinics.

✅Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/35201

Market Opportunities

Significant market opportunities exist in the rising prevalence of endocrine disorders such as thyroid dysfunction, adrenal insufficiencies, and diabetes. Increased health literacy, growing adoption of personalized medicine, and expansion of telehealth services are encouraging frequent testing and early intervention. Emerging technologies, such as saliva-based and wearable hormone monitoring devices, offer novel avenues for market expansion. Moreover, the growing demand for fertility testing and hormone replacement therapy diagnostics opens up new revenue streams for market players.

Reasons to Buy the Report

✔ Gain in-depth understanding of current and future trends in the endocrine testing market.
✔ Identify high-growth segments and regions to inform strategic investment decisions.
✔ Leverage competitive intelligence from top industry players and emerging startups.
✔ Understand the impact of technological advancements and regulatory changes on market dynamics.
✔ Access comprehensive market forecasts and actionable insights through 2032.

Company Insights

• Abbott Laboratories, Inc.
• AB Sciex Pte. Ltd.
• Agilent Technologies, Inc.
• bioMerieux SA
• Bio-Rad Laboratories Inc.
• DiaSorin S.p.A.
• F. Hoffmann-La Roche Ltd.
• Laboratory Corporation of America Holdings (LabCorp)
• Quest Diagnostics, Inc.
• Thermo Fisher Scientific, Inc.
• MP Biomedicals
• Ortho-Clinical Diagnostics (QuidelOrtho Corporation)
• Siemens Healthineers AG
• Sysmex Corporation

Recent Developments

In March 2025, Level Zero Health secured US$ 8.4 million in funding to develop a DNA-based sensor for continuous, remote hormone monitoring.

In January 2025, Eli Health launched the Hormometer, a saliva-based AI-driven hormone testing kit, at CES, revolutionizing real-time home diagnostics.

Conclusion

The global endocrine testing market is on a robust growth trajectory, fueled by increasing awareness of hormonal disorders, technological innovation, and expanding healthcare access worldwide. While North America leads the market, emerging economies in Asia Pacific and Latin America offer substantial growth potential. The shift toward personalized, preventive healthcare and the development of advanced home-based testing solutions are transforming the diagnostic landscape. Despite certain challenges such as high costs and limited infrastructure in some regions, the overall outlook remains highly positive. The market presents significant opportunities for stakeholders to innovate and scale, ultimately contributing to better global health outcomes through timely and accurate hormone testing.

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.